Effects on Immunological and Virological Outcome of Patients Using One Protease Inhibitor or One Non-Nucleoside Reverse Transcriptase Inhibitor in a Triple Antiretroviral Therapy: Normal Clinical Practice Versus Clinical Trial Findings

Publisher： Bentham Science Publishers

E-ISSN： 1873-4251|3|3|271-276

ISSN： 1570-162X

Source： Current HIV Research, Vol.3, Iss.3, 2005-07, pp. : 271-276

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor

By Sharma Mamta   Saravolatz Louis D.  

Journal of Antimicrobial Chemotherapy, Vol. 68, Iss. 2, 2013-02 ,pp. : 250-256

Oxford University Press

Access to resources Recommend Favorite

Evaluating the Role of Etravirine in the Second-Line Antiretroviral Therapy After Failing an Initial Non-Nucleoside Reverse Transcriptase Inhibitor- Based Regimen in a Resource-Limited Setting§

By  

Current HIV Research, Vol. 6, Iss. 5, 2008-09 ,pp. : 474-476

Bentham Science Publishers

Access to resources Recommend Favorite

Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding

By  

Current HIV Research, Vol. 2, Iss. 4, 2004-10 ,pp. : 323-332

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of Residues in the Nonnucleoside Reverse Transcriptase Inhibitor Binding Pocket on HIV-1 Reverse Transcriptase Heterodimer Stability

By  

Current HIV Research, Vol. 6, Iss. 2, 2008-03 ,pp. : 130-137

Bentham Science Publishers

Access to resources Recommend Favorite

Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome

By  

Cerebrovascular Diseases, Vol. 42, Iss. 5-6, 2016-07 ,pp. : 404-414

Karger

Access to resources Recommend Favorite